eliglustat

Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638).

THE MEDICAL NEWS Editors 2010

Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638).

THE MEDICAL NEWS Editors 2010

Genzyme is developing another potential Gaucher disease drug, called eliglustat tartrate, formerly Genz-112638; it is in late-stage development.

J. Weekly 2010

Genzyme is developing another potential Gaucher disease drug, called eliglustat tartrate, formerly Genz-112638; it is in late-stage development.

J. Weekly 2010

Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638).

THE MEDICAL NEWS 2010

Of course the other important element here is eliglustat, which is actively enrolling in two Phase 3 trials, and will be an even larger alternative on a global basis as we bring a third Phase 3 trial into enrollment later in the first half of this year.

SeekingAlpha.com: Home Page 2010

Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638).

THE MEDICAL NEWS 2010

These are Campath for treating multiple sclerosis; mipomersen, in development with Isis Pharmaceuticals Inc. for a rare cholesterol-related disorder; and eliglustat, an oral treatment for Gaucher's disease.

Genzyme Plans Buyback, to Shed Businesses 2010

As part of the agreement, ICIG will enter into a five-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in phase 3 clinical trials.

unknown title 2011

Within Genzyme's late-stage product pipeline, three product approvals are expected by the end of 2013: alemtuzumab for multiple sclerosis, mipomersen for familial hypercholesterolemia, and eliglustat tartrate for Type 1 Gaucher disease.

Genzyme Financial Recovery Continues in Fourth Quarter - Yahoo! Finance 2011